These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 16193576)

  • 21. Expanded access.
    Proj Inf Perspect; 1999 Apr; (27):13. PubMed ID: 11366730
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Some existing drugs work on resistant HIV.
    AIDS Alert; 2000 Jan; 15(1):10-2. PubMed ID: 11366357
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Amprenavir approved for HIV treatment.
    Miller SL
    Am J Health Syst Pharm; 1999 Jun; 56(11):1057-8. PubMed ID: 10385451
    [No Abstract]   [Full Text] [Related]  

  • 24. Drifting agenda for federal treatment research.
    Huff B
    GMHC Treat Issues; 2001 May; 15(5):1-4. PubMed ID: 11548299
    [No Abstract]   [Full Text] [Related]  

  • 25. [New therapeutic options in protracted HIV-infected patients with virological failure].
    Moreno Cuerda VJ; Rubio García R; Morales Conejo M
    Med Clin (Barc); 2008 Jan; 130(2):66-70. PubMed ID: 18221677
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tipranavir in the protease inhibitors arena.
    Vergani B; Rusconi S
    Drugs R D; 2011 Dec; 11(4):291-3. PubMed ID: 22133386
    [No Abstract]   [Full Text] [Related]  

  • 27. European Commission grants full approval for Aptivus.
    AIDS Patient Care STDS; 2008 May; 22(5):438. PubMed ID: 18521974
    [No Abstract]   [Full Text] [Related]  

  • 28. FDA approval: darunavir.
    Sax PE
    AIDS Clin Care; 2006 Aug; 18(8):71. PubMed ID: 16906668
    [No Abstract]   [Full Text] [Related]  

  • 29. FDA notifications. New tipranavir solution approved.
    AIDS Alert; 2008 Aug; 23(8):92. PubMed ID: 18724491
    [No Abstract]   [Full Text] [Related]  

  • 30. Drug resistance mutations in HIV-infected patients in the Spanish drug resistance database failing tipranavir and darunavir therapy.
    Poveda E; Anta L; Blanco JL; Casado JL; Gutiérrez F; García F; Gómez-Sirvent JL; Iribarren JA; Soriano V; de Mendoza C;
    Antimicrob Agents Chemother; 2010 Jul; 54(7):3018-20. PubMed ID: 20479204
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anti-HIV agents. Unexpected results from a tipranavir study.
    TreatmentUpdate; 2004; 16(3):6-7. PubMed ID: 17216836
    [No Abstract]   [Full Text] [Related]  

  • 32. Anti-HIV agents. Tipranavir in treatment-experienced PHAs.
    TreatmentUpdate; 2005; 17(1):4-5. PubMed ID: 17225315
    [No Abstract]   [Full Text] [Related]  

  • 33. Reviving protease inhibitors: new data and more options.
    Murphy RL
    J Acquir Immune Defic Syndr; 2003 Jun; 33 Suppl 1():S43-52; quiz S53, S55-6. PubMed ID: 12946064
    [No Abstract]   [Full Text] [Related]  

  • 34. FDA approves darunavir.
    AIDS Patient Care STDS; 2008 Dec; 22(12):1021-2. PubMed ID: 19097261
    [No Abstract]   [Full Text] [Related]  

  • 35. Boehringer drug for resistant HIV approved.
    AIDS Read; 2005 Aug; 15(8):379, 391. PubMed ID: 16110551
    [No Abstract]   [Full Text] [Related]  

  • 36. Darunavir-etravirine-raltegravir as salvage combination therapy in a heavily pretreated HIV-infected patient.
    Vento S; Vallone A
    AIDS Patient Care STDS; 2008 Nov; 22(11):841-2. PubMed ID: 19025477
    [No Abstract]   [Full Text] [Related]  

  • 37. HIV protease inhibitors: recent clinical trials and recommendations on use.
    Fernández-Montero JV; Barreiro P; Soriano V
    Expert Opin Pharmacother; 2009 Jul; 10(10):1615-29. PubMed ID: 19527188
    [TBL] [Abstract][Full Text] [Related]  

  • 38. FDA notifications. FDA OKs new pediatric dosing for darunavir.
    AIDS Alert; 2009 Feb; 24(2):22-4. PubMed ID: 19222149
    [No Abstract]   [Full Text] [Related]  

  • 39. TMC114 approved for resistant patients.
    AIDS Patient Care STDS; 2006 Oct; 20(10):731. PubMed ID: 17052143
    [No Abstract]   [Full Text] [Related]  

  • 40. Evidence for different susceptibility to tipranavir and darunavir in patients infected with distinct HIV-1 subtypes.
    Poveda E; de Mendoza C; Parkin N; Choe S; García-Gasco P; Corral A; Soriano V
    AIDS; 2008 Mar; 22(5):611-6. PubMed ID: 18317002
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.